argenx SE (LTS:0QW0) Other Income (Expense) : €-32 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is argenx SE Other Income (Expense)?

argenx SE's other income expense for the argenx SE's pretax income for the three months ended in Dec. 2024 was €-33 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-32 Mil.

argenx SE Other Income (Expense) Historical Data

The historical data trend for argenx SE's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Other Income (Expense) Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

-106.45

-37.38

-26.38

22.09

-31.76

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Income (Expense)	Get a 7-Day Free Trial															45.90	-19.42	-8.76	28.78	-33.11

argenx SE Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32 Mil.

argenx SE (LTS:0QW0) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (LTS:0QW0) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGNF:USA ARGXb:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines